Literature DB >> 26559459

HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.

Bob T Li1, Adrian Lee2, Sandra O'Toole3, Wendy Cooper4, Bing Yu5, Jamie E Chaft6, Maria E Arcila7, Mark G Kris6, Nick Pavlakis8.   

Abstract

Human epidermal growth factor 2 (HER2, ERBB2) mutations in lung cancers are oncogenic drivers that respond to HER2 targeted therapies. Little is known about the sensitivity of subtypes of HER2 mutant lung cancers to targeted agents. We present a patient with HER2 mutant lung cancer with a 12 base pair insertion YVMA (p.A775_G776insYVMA), who had a long natural history and durable partial response to afatinib. We demonstrate that afatinib has activity in patients with HER2 mutant lung cancers with exon 20 YVMA insertions, the most common variant.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Afatinib; Human epidermal growth factor receptor 2 (HER2); Lung cancer; Mutation; Targeted therapy

Mesh：

Substances：

Year:  2015        PMID： 26559459      PMCID： PMC4724317          DOI： 10.1016/j.lungcan.2015.10.025

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  8 in total

1.  Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma.

Authors:  Zoltan Lohinai; Mir Alireza Hoda; Katalin Fabian; Gyula Ostoros; Erzsebet Raso; Tamas Barbai; Jozsef Timar; Ilona Kovalszky; Mihaly Cserepes; Anita Rozsas; Viktoria Laszlo; Michael Grusch; Walter Berger; Walter Klepetko; Judit Moldvay; Balazs Dome; Balazs Hegedus
Journal:  J Thorac Oncol       Date:  2015-05       Impact factor: 15.609

2.  A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.

Authors:  A Suder; J E Ang; F Kyle; D Harris; S Rudman; R Kristeleit; F Solca; M Uttenreuther-Fischer; K Pemberton; K Pelling; D Schnell; J de Bono; J Spicer
Journal:  Eur J Cancer       Date:  2015-08-18       Impact factor: 9.162

3.  Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.

Authors:  Jacques De Grève; Teresa Moran; Marie-Pascale Graas; Daniella Galdermans; Peter Vuylsteke; Jean-Luc Canon; Denis Schallier; Lore Decoster; Erik Teugels; Dan Massey; Vikram K Chand; Johan Vansteenkiste
Journal:  Lung Cancer       Date:  2015-01-23       Impact factor: 5.705

4.  Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

Authors:  Maria E Arcila; Jamie E Chaft; Khedoudja Nafa; Sinchita Roy-Chowdhuri; Christopher Lau; Michael Zaidinski; Paul K Paik; Maureen F Zakowski; Mark G Kris; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2012-07-03       Impact factor: 12.531

5.  Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

Authors:  J De Grève; E Teugels; C Geers; L Decoster; D Galdermans; J De Mey; H Everaert; I Umelo; P In't Veld; D Schallier
Journal:  Lung Cancer       Date:  2012-02-10       Impact factor: 5.705

6.  Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

Authors:  Julien Mazières; Solange Peters; Benoit Lepage; Alexis B Cortot; Fabrice Barlesi; Michéle Beau-Faller; Benjamin Besse; Hélène Blons; Audrey Mansuet-Lupo; Thierry Urban; Denis Moro-Sibilot; Eric Dansin; Christos Chouaid; Marie Wislez; Joachim Diebold; Enriqueta Felip; Isabelle Rouquette; Julie D Milia; Oliver Gautschi
Journal:  J Clin Oncol       Date:  2013-04-22       Impact factor: 44.544

7.  Lung cancer: intragenic ERBB2 kinase mutations in tumours.

Authors:  Philip Stephens; Chris Hunter; Graham Bignell; Sarah Edkins; Helen Davies; Jon Teague; Claire Stevens; Sarah O'Meara; Raffaella Smith; Adrian Parker; Andy Barthorpe; Matthew Blow; Lisa Brackenbury; Adam Butler; Oliver Clarke; Jennifer Cole; Ed Dicks; Angus Dike; Anja Drozd; Ken Edwards; Simon Forbes; Rebecca Foster; Kristian Gray; Chris Greenman; Kelly Halliday; Katy Hills; Vivienne Kosmidou; Richard Lugg; Andy Menzies; Janet Perry; Robert Petty; Keiran Raine; Lewis Ratford; Rebecca Shepherd; Alexandra Small; Yvonne Stephens; Calli Tofts; Jennifer Varian; Sofie West; Sara Widaa; Andrew Yates; Francis Brasseur; Colin S Cooper; Adrienne M Flanagan; Margaret Knowles; Suet Y Leung; David N Louis; Leendert H J Looijenga; Bruce Malkowicz; Marco A Pierotti; Bin Teh; Georgia Chenevix-Trench; Barbara L Weber; Siu T Yuen; Grace Harris; Peter Goldstraw; Andrew G Nicholson; P Andrew Futreal; Richard Wooster; Michael R Stratton
Journal:  Nature       Date:  2004-09-30       Impact factor: 49.962

8.  Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.

Authors:  M G Kris; D R Camidge; G Giaccone; T Hida; B T Li; J O'Connell; I Taylor; H Zhang; M E Arcila; Z Goldberg; P A Jänne
Journal:  Ann Oncol       Date:  2015-04-21       Impact factor: 32.976
  8 in total
  17 in total

Review 1.  Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers.

Authors:  Janakiraman Subramanian; Archana Katta; Ashiq Masood; Dashavantha Reddy Vudem; Rama Krishna Kancha
Journal:  Oncologist       Date:  2019-07-10

Review 2.  Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.

Authors:  Bin-Chi Liao; Chia-Chi Lin; James Chih-Hsin Yang
Journal:  Curr Oncol Rep       Date:  2017-01       Impact factor: 5.075

3.  Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

Authors:  Bob T Li; Ronglai Shen; Darren Buonocore; Zachary T Olah; Ai Ni; Michelle S Ginsberg; Gary A Ulaner; Michael Offin; Daniel Feldman; Todd Hembrough; Fabiola Cecchi; Sarit Schwartz; Nick Pavlakis; Stephen Clarke; Helen H Won; Edyta B Brzostowski; Gregory J Riely; David B Solit; David M Hyman; Alexander Drilon; Charles M Rudin; Michael F Berger; Jose Baselga; Maurizio Scaltriti; Maria E Arcila; Mark G Kris
Journal:  J Clin Oncol       Date:  2018-07-10       Impact factor: 44.544

4.  Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation.

Authors:  Jian Wang; Yuxin Wen; Guanggui Ding; Peikun Ding; Lu Zhang; Jing Liu; Tengfei Zhang; Lin Yang
Journal:  Cancer Biol Ther       Date:  2018-04-12       Impact factor: 4.742

5.  Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.

Authors:  Birgit Wilding; Dirk Scharn; Dietrich Böse; Anke Baum; Valeria Santoro; Paolo Chetta; Renate Schnitzer; Dana A Botesteanu; Christoph Reiser; Stefan Kornigg; Petr Knesl; Alexandra Hörmann; Anna Köferle; Maja Corcokovic; Simone Lieb; Guido Scholz; Jens Bruchhaus; Markus Spina; Josef Balla; Biljana Peric-Simov; Jasmin Zimmer; Sophie Mitzner; Thomas N Fett; Alexandra Beran; Lyne Lamarre; Thomas Gerstberger; Daniel Gerlach; Markus Bauer; Andreas Bergner; Andreas Schlattl; Gerd Bader; Matthias Treu; Harald Engelhardt; Stephan Zahn; Julian E Fuchs; Johannes Zuber; Peter Ettmayer; Mark Pearson; Mark Petronczki; Norbert Kraut; Darryl B McConnell; Flavio Solca; Ralph A Neumüller
Journal:  Nat Cancer       Date:  2022-07-26

6.  Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.

Authors:  Juliana Eng; Meier Hsu; Jamie E Chaft; Mark G Kris; Maria E Arcila; Bob T Li
Journal:  Lung Cancer       Date:  2016-05-31       Impact factor: 5.705

7.  Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.

Authors:  W Victoria Lai; Louisiane Lebas; Tristan A Barnes; Julie Milia; Ai Ni; Oliver Gautschi; Solange Peters; Roberto Ferrara; Andrew J Plodkowski; John Kavanagh; Joshua K Sabari; Stephen J Clarke; Nick Pavlakis; Alexander Drilon; Charles M Rudin; Maria E Arcila; Natasha B Leighl; Frances A Shepherd; Mark G Kris; Julien Mazières; Bob T Li
Journal:  Eur J Cancer       Date:  2019-01-24       Impact factor: 9.162

Review 8.  A narrative review of advances in treatment and survival prognosis of HER2-positive malignant lung cancers.

Authors:  Ranpu Wu; Bingxiao Yuan; Chuling Li; Zimu Wang; Yong Song; Hongbing Liu
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

Review 9.  Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.

Authors:  Ravi Salgia
Journal:  Expert Rev Mol Diagn       Date:  2016-05-26       Impact factor: 5.225

10.  Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes.

Authors:  Laura J Tafe; Kirsten J Pierce; Jason D Peterson; Francine de Abreu; Vincent A Memoli; Candice C Black; Jason R Pettus; Jonathan D Marotti; Edward J Gutmann; Xiaoying Liu; Keisuke Shirai; Konstantin H Dragnev; Christopher I Amos; Gregory J Tsongalis
Journal:  Neoplasia       Date:  2016-09       Impact factor: 5.715
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.